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Abstract: 
Objective: To determine the frequency of nasopharyngeal angiofibroma in patients presenting with recurrent epistaxis. 
Study design: Cross sectional study. 
Duration and setting: This study was carried out from July 2017 to July 2018 at ENT, Head & Neck Surgery department, Khyber 
teaching hospital, Peshawar.  
Material and method: A total number of 93 patients were included in this study. Patients fulfilling the inclusion  criteria were 
collected from the outdoor patient department (OPD)  of  ENT,  head   and  neck  surgery, Khyber teaching hospital, Peshawar.  
Informed consent for participating in the study was taken from all patients. The patients’ biodata   along with hospital 
registration number were entered on proforma. The patients were assessed initially by history and nasal endoscopic. CT scan 
nose and PNS with contrast was done and patient admitted and operated for the suspected nasopharyngeal angiofibroma. Biopsy 
specimen was sent for histopathology to consultant histopathologist in the hospital’s pathology laboratory. Lab reports of the 
biopsy specimen  showing histopathology of nasopharyngeal angiofibroma  were reviewed and data entered  in  the  proforma.  
Results: Out of 93 patients, 32% patients were in age range 10-15 years, 68% patients were in age range 16-20 years. Mean age 
was 16 years with SD ± 1.26.  Fifty seven percent patients had duration of symptoms <1 year while 43% patients had duration of 
symptoms > 1 year. The incidence of nasopharyngeal angiofibroma was 18%. Conclusion: Our study concludes that the 
incidence of nasopharyngeal angiofibroma in our setup is 18% which can be due to the increasing number of Afghan refugees.  
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INTRODUCTION: 
Nasopharyngeal Angiofibroma (also known as 
juvenile nasopharyngeal angiofibroma; JNA) is a 
benign fibrovascular tumor that occurs in the 
nasopharynx of prepubertal and adolescent males but 
locally aggressive neoplasm that exhibiting a strong 
tendency to bleed. [1,2] Hippocrates described the 
tumor in 5th century BC and Chauveau first used the 
term angiofibroma in 1906. [3] The incidence of JNA 
is 0.05 - 0.5% of all head and neck tumors in US with 
wide geographical variation, India being highe. 
[4,5,6,7] Pathologically, it is characterized by 
haphazardly arranged vascular channels surrounded 
by dense fibrous tissue. The smaller vessels in the 
central portion of the lesion typically lack muscular 
elastic laminae which contribute to the capacity for 
massive bleeding. Although angiofibroma is 
histologically benign, it may act in an aggressive 
fashion characterized by recurrences that may extend 
into and destroy the adjacent bony structures. The 
extent of growth is studied clinically and 
radiologically by contrast enhanced computerized 
tomography (CT) scans and staged accordingly. [8,9] 
 
The most common presenting symptoms are painless 
nasal obstruction, repeated nasal bleeding, and a 
nasal or nasopharyngeal mass with nonspecific 
symptoms of rhinorrhea, anosmia, and headache. 
Facial deformity, protrusion of eyes, exophthalmos, 
visual disturbance, cranial nerve paralysis, and 
neurologic deficits suggest advanced disease. 
[4,10,11] 
 
The diagnosis of Nasopharyngeal Angiofibroma is 
essentially based on a careful history and nasal 
endoscopic examination, supplemented by imaging 
studies using computed tomogram (CT) and 
Magnetic Resonance Imaging (MRI). MRI is more 
accurate than CT in assessing intracranial extension. 
Preoperative Biopsies to establish histological 
diagnosis are contraindicated for fear of massive 
lethal bleeding and definitive diagnosis is established 
by angiography which also serves as therapy since 
embolization of the tumor feeding vessels may be 
performed at the same sitting. Preoperative 
embolization minimizes intraoperative blood loss. It 
can be safely performed without neurological 
complications. Angiography is helpful in delineating 
internal carotid system supply and can help guide 
surgical planning. [12,13,14] 
 
The management of Nasopharyngeal Angiofibroma 
presents a challenge to ENT surgeons. Preoperative 
angiography and embolization minimize 
intraoperative blood loss and the current shift in the 
treatment to endoscopic excision in selected lesions 
reduces perioperative morbidity. Progress in skull 
base anatomy, instrumentation, cameras, and surgical 
strategy allows for expansion of the indications for 
endoscopic removal of Nasopharyngeal 
Angiofibroma. This approach may have a better 
outcome in terms of blood loss, hospital stay, and 
local sequelae. Still, an external approach should be 
considered only for selected cases due to massive 
intracranial extension or optic nerve or internal 
carotid artery entrapment by the tumor. An efficient 
strategy in the management of extensive 
Nasopharyngeal Angiofibroma is the use of a 
multimodality approach, in which surgical resection 
is followed by the treatment with radiosurgery in 
critical locations. These therapeutic schemes are safe 
and offer long-term tumor control….12. [15,16,17] 
For selected tumors with limited infratemporal fossa 
invasion and skull base erosion, the endoscopic 
approach may also be indicated. It is a safe and 
effective treatment modality due to the lack of 
external scars, minimal bone resection and blood loss 
and low recurrence rate….1. [19,20,21]. 
 
The purpose of the study is to determine the 
frequency of Nasopharyngeal Angiofibroma in male 
patients presenting with recurrent and profuse 
epistaxis because epistaxis is a very common 
problem and a number of patients present with 
profuse and recurrent epistaxis. Knowing that 
angiofibroma if diagnosed early and treated 
promptly, gives good results in terms of eradicating 
the problem, minimizing risks of recurrence and 
avoiding complications. If missed in such patients, 
angiofibroma can lead to serious complications and 
even death. 
 
MATERIAL AND METHOD:  
A total number of 93 patients were included in this 
cross sectional study with Convenience non 
probability sampling from July 2017 to July 2018. 
Patients fulfilling  the  inclusion  criteria were 
collected from the outdoor patient department  of  
ENT,  head   and  neck  surgery, Khyber teaching 
hospital, Peshawar. Only Male patients having age 
10-20 years with recurrent epistaxis were included in 
the study, while patients Previously diagnosed or 
recurrent cases of Nasopharyngeal Angiofibroma. 
And   Patients with clinical suspicion of Sino nasal 
Polyposis were excluded from study. Informed 
consent for participating in the study was taken from 
all patients. The patients’ biodata   along with 
hospital registration number were entered on 
proforma. The patients were assessed initially by 
history and nasal endoscopic examination. CT scan 
nose and PNS with contrast was done and patient 
admitted and operated for the suspected 
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nasopharyngeal angiofibroma. Biopsy specimen was 
sent for histopathology to consultant histopathologist 
in the hospital’s pathology laboratory. Reports  of the 
biopsy specimen  showing histopathology of 
nasopharyngeal angiofibroma  were reviewed and 
data entered  in  the  proforma. 
 
Operational definitions:  
Recurrent Epistaxis:  
The patients, who were present with at least 03 bouts 
of nasal bleed within 01 month, (at least 15 drops of 
blood in each bout) were considered as recurrent 
epistaxis. 
 
Nasopharyngeal Angiofibroma:  
It was mean any visible mass in the nasal cavity (seen 
through anterior rhinoscopy with kalian nasal 
speculum or nasal endoscopy) or in nasopharynx 
(hyperdense mass seen in nasopharynx with Contrast 
enhanced CT scan) in adolescent males. 
 
Data analysis:  
The data was stored and analyzed in SPSS version 
17. Descriptive statistics like mean + standard 
deviation was calculated for quantitative variables 
(age and duration of symptoms). Frequency and 
percentages were calculated for categorical variable 
(Angiofibroma). Nasopharyngeal Angiofibroma were 
stratified among age and duration of symptoms to 
control effect modification. Post stratification was 
done through chi-square test. P value ≤ 0.05 was 
considered significant. All the results were 
represented as tables/charts.      
 
RESULTS:  
A total of 93 patients were observed to determine the 
frequency of nasopharyngeal angiofibroma in 
recurrent epistaxis and the results were analyzed as: 
 
Age distribution among 93 patients was analyzed as 
30 (32%) patients were in age range 10-15 years, 
63(68%) patients were in age range 16-20 years. 
Mean age was 16 years with SD ± 1.26. (as shown in 
Table No 1). Duration of symptoms among 93 
patients was analyzed as 53(57%) patients had 
duration of symptoms < 1 year while 40(43%) 
patients had duration of symptoms > 1 year. (as 
shown in table No 2). Nasopharyngeal angiofibroma 
among 93 patients was analyzed as 17(18%) patients 
had nasopharyngeal angiofibroma while 76(82%) 
patients didn’t had nasopharyngeal angiofibroma. (as 
shown in table No 3). Stratification of frequency of 
nasopharyngeal angiofibroma with age and duration 
of symptoms is given in table no 4,5 
 
Table No. 1  Age Distribution (n=93) 
 
Age Frequency Percentage 
10-15 years 30 32% 
16-20 years 63 68% 
Total 93 100% 
 
Mean age was 16 years with SD ± 1.26 
 
Table No. 2 Duration of symptoms (n=93) 
 
Duration of symptoms Frequency Percentage 
< 1 year 53 57% 
>1 year 40 43% 
Total 93 100% 
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Table No. 3 Nasopharyngeal angiofibroma  (n=93) 
Nasopharyngeal 
angiofibroma 
Frequency Percentage 
Present  17 18% 
Absent  76 82% 
Total 93 100% 
 
 
 
Table No. 4 Stratification Of Nasopharyngeal Aangiofibroma with Age (n=93) 
Nasopharyngeal 
angiofibroma 
10-15 years 16-20 years Total 
Present 5 12 17 
Absent 25 51 76 
Total 30 63 93 
 
Chi Square test was applied in which P value was 0.002 
 
Table No. 5. Stratification of Nasopharyngeal Angiofibroma with Duration of Symptoms  (n=93) 
Nasopharyngeal 
angiofibroma 
< 1 year >1 year Total 
Present 10 7 17 
Absent 43 33 76 
Total 53 40 93 
 
Chi Square test was applied in which P value was 0.003 
 
DISCUSSION:  
Juvenile nasopharyngeal Angiofibroma (JNA) is a 
lobulated, firm non-capsulated tumour with 
numerous attachment and multiple feeding vessels. 
Diagnosis is relied upon clinical and radiological 
findings where as the ultimate histopathological 
diagnosis comes from surgical specimen. Recurrent 
epistaxis and bleeding during surgery is hazardous at 
time. Pre-operative super selective embolization has 
made the dissection feasible for surgeons. Surgery is 
considered the mainstay of all available treatment 
modality in this tumor. 
 
Our study shows that 32% patients were in age range 
10-15 years, 68% patients were in age range 16-20 
years. Mean age was 16 years with SD ± 1.26.  Fifty 
seven percent patients had duration of symptoms <1 
year while 43% patients had duration of symptoms > 
1 year. More over in our study the incidence of 
nasopharyngeal angiofibroma was 18% patients in 
which 7(40%) patients were Afghan refugees. Similar 
results were observed in other studies as:  
 
Shahabi I et al [22] the region wise incidence of 
Angiofibroma in a study of 20 cases was ranging 
from 10-40% with maximum incidence in afghan 
refugees as 40%.In study conducted by Ghias K et al, 
the incidence of Nasopharyngeal Angiofibroma is 
ambiguous; some studies estimate it to be 0.5%, 
whereas others claim it to be even rarer, having an 
incidence of 0.05% of all tumors of the head and 
neck region. The incidence of JNA in South Asia 
appears to be greater than in the West.23 Though in 
Pakistan the exact incidence is not known, patients 
mainly present from the rural areas of Sindh and 
Baluchistan. More over for stage I and II tumors, the 
current practice and standard of care is the use of 
trans nasal endoscopic surgery. In their review, the 
early staged tumors were treated by open procedures, 
primarily because of lack of surgical expertise. These 
were essentially treated by General Otolaryngologists 
with limited experience and training in endoscopic 
Sino nasal techniques. [24] 
 
Extensive tumors tend to present at a younger age. 
This may be attributed to the increased frequency of 
epistaxis, culminating in earlier consultation. While a 
study describes greater degree of maturation and 
small number of blood vessels supplying large JNAs. 
[23] Shamim AA et al study revealed expansion in 
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blood supply when the tumor became advanced. In 
their study, the percentage of tumors supplied 
bilaterally increased from 25% to 100% as the stage 
of the tumor progressed from I to IV. All patients 
were embolized pre-operatively, comparable to 
literature. [24] 
  
Reported recurrence rates following treatment of 
JNA varies between 0 and 55%. [25] The 10.5% 
(2/19) recurrence rate in the present study is less than 
the rate of 17% (7/42) reported earlier. [26] However, 
in the earlier study, if only the group of patients 
treated via conventional surgery is taken into 
account, the recurrence rate was 23% (7/30) as all 
recurrences resulted from traditional approaches and 
none endoscopically. Others reported a rate of 
residual tumor of 13.5% (5/37) which is comparable 
to the 15.8% (3/19). [27]  
 
CONCLUSION:  
Our study concludes that the incidence of 
nasopharyngeal angiofibroma in our setup is 18% 
which can be due to the increasing number of Afghan 
refugees.  
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